Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
about
Prevalence of irritable bowel syndrome: a community survey.Stress and visceral pain: from animal models to clinical therapiesEffect of 5-HT1 agonist (sumatriptan) on anorectal function in irritable bowel syndrome patients.Review article: the pharmacological treatment of acute colonic pseudo-obstruction.Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome.Characterization of human 5-HT4(d) receptor desensitization in CHO cells.5-HT7 receptors mediate the inhibitory effect of 5-HT on peristalsis in the isolated guinea-pig ileumRole of serotonin in the pathophysiology of the irritable bowel syndrome.Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases.Pharmacological treatment of irritable bowel syndrome: a critical assessment.Pharmacology of serotonin: what a clinician should know.Gastrointestinal pain in functional bowel disorders: sensory neurons as novel drug targets.Schisandra chinensis reverses visceral hypersensitivity in a neonatal-maternal separated rat model.Effect of areca on contraction of colonic muscle strips in rats.Drugs acting on serotonin receptors for the treatment of functional GI disorders.Histopathological alterations in irritable bowel syndrome.Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity.The role of the serotonergic system in suicidal behaviorActivation of 5-HT and NR2B contributes to visceral hypersensitivity in irritable bowel syndrome in ratsIrritable bowel syndrome: emerging paradigm in pathophysiology.Contributions of the microbial hydrogen economy to colonic homeostasis.Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome.Reversal of inflammatory and noninflammatory visceral pain by central or peripheral actions of sumatriptanSerotonin hormonally regulates lacrimal gland secretory function via the serotonin type 3a receptor.Effect of enterokinetic prucalopride on intestinal motility in fast rats.Serotonin 5-HT7 receptor is critically involved in acute and chronic inflammation of the gastrointestinal tract.Treatment functional GI disease: the complex pharmacology of serotonergic drugs.Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.Intestinal motor stimulation by the 5-HT4 receptor agonist ML10302: differential involvement of tachykininergic pathways in the canine small bowel and colon.Serotonin and cholecystokinin synergistically stimulate rat vagal primary afferent neurones.Phytotherapeutic effects of the fruits of Poncirus trifoliata (L.) Raf. on cancer, inflammation, and digestive dysfunction.Effects of curcumin and Ginkgo biloba on matrix metalloproteinases gene expression and other biomarkers of inflammatory bowel disease.Psychiatric disorders and association with quality of sleep and quality of life in patients with chronic pain: a SCID-based study.Migrating motor complex in colectomized ileo stoma patients.
P2860
Q24535897-37C9B05B-08F1-4B79-AF37-5A623F60B143Q30459512-6A0E9EA7-6144-4F7D-9D09-ABC172754847Q34012595-0F9251B2-D1BA-404B-8875-37E707F5597AQ34421482-5F7CE017-5F16-46F2-AB0B-7BC5171AC624Q34992347-AEE029FD-2581-4951-99B0-D10935BBA357Q35044960-CD9BB1F4-EB7C-4498-AD43-A321EFCA30B7Q35045189-229BDED1-E667-4CE1-AFEE-3C01524AA1BEQ35047066-3AEFBCBF-E541-4822-9209-1F7E1F937A78Q35143893-CCD486D6-A88B-4222-BD4F-61A442A0CCB3Q35585701-E860BD64-2E25-49CC-B6FB-8F1F47EDB3AAQ35596862-E0C03C89-D049-4176-81D2-F4FDAF60CFE5Q35753361-5F62085B-1B42-4222-AF0A-F8AD3C5E4EBDQ35809437-8D13806B-ABE5-478C-B021-5FB3ECCBBEA4Q36316132-9D383653-A4E0-47C5-8D8D-92147782494EQ36478089-A22F6EB2-DBCA-464D-B915-0B0A455D9DFFQ36609410-82E0D29A-C997-4537-ABE2-DDA681DDF23BQ36728938-C9CC6403-1C47-4EAC-9A52-76A99A4CA4E5Q37302663-75C32810-3A3B-45CE-9EAF-9B966FECABE0Q37553829-C8997167-6E08-4888-8B39-697806698FB2Q37629670-507101C5-B2C0-4CE7-801E-F4DF96059B18Q38010069-21C56E8B-2996-4663-B75C-5631071CAC1DQ38178543-1B747C84-3CD6-454B-8CB8-2E90D1118C4FQ39810939-54BBA021-79DB-4D8B-A79A-047821509445Q41191875-375370A8-FB68-43F3-A654-C9E3CF528A25Q42079920-3D5102B8-25FF-46BD-816D-44F52038079FQ42463124-D16EFCEA-68AC-4F86-8DF4-CD66B6D74EFDQ42780042-1CEEAFD2-290A-48A9-8181-E25CD9B4527DQ43171523-2F8C10C9-3438-422E-89A0-B844B55FBB3FQ43923608-87E3ECAB-4B73-4C70-9F7C-7BD6CB861374Q44964682-9837FA7A-A14E-45CE-AD54-9341F4217660Q46237715-80B673E3-CBA8-4F57-B319-BF09A94A68EFQ46688546-FE292D44-C213-4C45-B31B-9B465974EC89Q48083597-ACD40C2C-3955-43C2-BD32-F74F41BD904BQ51382749-95487372-15C3-49AA-9F79-2A2E5894C7DE
P2860
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
@ast
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
@en
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
@nl
type
label
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
@ast
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
@en
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
@nl
prefLabel
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
@ast
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
@en
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
@nl
P1433
P1476
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
@en
P2093
P304
P356
10.2165/00003495-200161030-00001
P577
2001-01-01T00:00:00Z
P6179
1045559343